SMS PHARMACEUTICALS LTD. - 532815 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation of Schedule of Analyst / Institutional Investor meeting12-04-2022
12-04-2022
SMS PHARMACEUTICALS LTD. - 532815 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 201811-04-2022
SMS PHARMACEUTICALS LTD. - 532815 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation of Schedule of Analyst / Institutional Investor meetings under the SEBI (LODR) Regulations, 2015.06-04-2022
SMS PHARMACEUTICALS LTD. - 532815 - Closure of Trading Window
Intimation of Trading Window closure31-03-2022
SMS PHARMACEUTICALS LTD. - 532815 - Disclosure of Voting results of Postal Ballot (Regulation 44(3) of SEBI (LODR) Regulations, 2015)
SMS Pharmaceuticals Ltd has informed BSE regarding the details of Voting results of Postal Ballot, under Regulation 44(3) of SEBI (LODR) Regulations, 2015. Kindly Click here31-03-2022
SMS PHARMACEUTICALS LTD. - 532815 - Submission Of Voting Results Of Postal Ballot And Scrutinizer'S Report
Submission of Voting Results of Postal Ballot and Scrutinizer's Report30-03-2022
SMS PHARMACEUTICALS LTD. - 532815 - Completion Of Remote Regulatory Assessment By United States Food And Drug Administration (USFDA).
Completion of remote regulatory assessment by United States Food and Drug Administration (USFDA).21-03-2022
SMS Pharmaceuticals share price zooms after bagging licence to manufacture, supply oral COVID vaccines
SMS Pharmaceuticals has received a non-exclusive license to manufacture and supply of nirmatrelvir through the Medicine Patent Pool to manufacture nirmatrelvir, an oral anti-viral Covid-19 medicine.21-03-2022
SMS PHARMACEUTICALS LTD. - 532815 - SMS Pharmaceuticals Limited receives non-exclusive license to manufacture and supply of nirmatrelvir (an oral COVID-19 medicine) through the Medicine Patent Pool (MPP)
SMS Pharmaceuticals Ltd has informed BSE regarding a Press Release dated March 17, 2022 titled "SMS Pharmaceuticals Limited receives non-exclusive license to manufacture and supply of nirmatrelvir (an oral COVID-19 medicine) through the Medicine Patent Pool (MPP)".18-03-2022
SMS PHARMACEUTICALS LTD. - 532815 - Intimation Of Schedule Of Analyst / Institutional Investor Meetings
Intimation of Schedule of Analyst / Institutional Investor meetings11-03-2022